Mr. Holme has a strong interdisciplinary scientific background with approximately 30 years experience in pharmaceutical research and development, initially working as a medicinal chemist and then later in pharmaceutical development, and more broadly in development program leader roles in small start-up biotech companies.
Prior to joining Amplyx, Mr. Holme was a co-founder and COO of PharmAkea Inc. (2012 to 2016), a private biopharmaceutical start-up in San Diego, responsible for all Development activities (CMC, nonclinical, clinical and regulatory) in a virtual development environment. Before PharmAkea, Mr. Holme was Executive Director of Development at Amira Pharmaceuticals, where he was responsible for CMC, Nonclinical and Clinical planning across multiple projects, leading to three successful Phase 1 candidates, and multiple partnerships including an LPA1 receptor antagonist that was the subject of a $475 million acquisition of Amira by BMS. Prior to Amira, Mr. Holme held R&D management positions at SGX Pharmaceuticals, Trega Biosciences/LION Bioscience and Ligand Pharmaceuticals/Glycomed Inc. Since 2010, he has maintained some external consulting relationships around CMC and early development due diligence, for companies including Aragon, Seragon, Receptos, Lumena, Reneo, Amplyx and Curzion.
Mr. Holme received a B.Sc. (Honors) in Chemistry from Carleton University, Ottawa, Canada, and a Ph.D. (Honors) in Chemistry from the University of British Columbia, Vancouver, Canada. He completed postdoctoral studies in Chemistry at McGill University in Montreal, Canada, and an industrial postdoctoral term at IAF Biochem (later Biochem Pharma).